Susan Moran
Directeur/Membre du Conseil chez BIOATLA, INC.
Fortune : - $ au 30/04/2024
Postes actifs de Susan Moran
Sociétés | Poste | Début | Fin |
---|---|---|---|
BIOATLA, INC. | Directeur/Membre du Conseil | 01/12/2020 | - |
Independent Dir/Board Member | 01/12/2020 | - | |
TYRA BIOSCIENCES, INC. | Directeur/Membre du Conseil | 07/05/2024 | - |
Independent Dir/Board Member | 07/05/2024 | - |
Historique de carrière de Susan Moran
Anciens postes connus de Susan Moran
Sociétés | Poste | Début | Fin |
---|---|---|---|
RAYZEBIO, INC. | Directeur Technique/Scientifique/R&D | 01/07/2021 | 01/05/2024 |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Directeur Technique/Scientifique/R&D | 01/03/2018 | 01/06/2021 |
PUMA BIOTECHNOLOGY, INC. | Directeur Technique/Scientifique/R&D | 01/01/2014 | 01/02/2018 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Directeur Technique/Scientifique/R&D | 01/01/2011 | 01/01/2014 |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Directeur Technique/Scientifique/R&D | 01/01/2007 | 01/01/2011 |
Formation de Susan Moran
University of Virginia | Undergraduate Degree |
University of Pennsylvania Medical Center | Graduate Degree |
Duke University | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 10 |
Royaume-Uni | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 5 |
Director/Board Member | 2 |
Independent Dir/Board Member | 2 |
Sectorielle
Health Technology | 8 |
Consumer Services | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 4 |
---|---|
BIOATLA, INC. | Health Technology |
PUMA BIOTECHNOLOGY, INC. | Health Technology |
RAYZEBIO, INC. | Health Technology |
TYRA BIOSCIENCES, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Bourse
- Insiders
- Susan Moran
- Expérience